Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857478 | 0.82 | MAP2K4 (0.52) | MAPK1MAPK3FLT3MAP4K1 | |
| SCHEMBL2864256 | 0.82 | MAP2K4 (0.52) | MAPK1MAPK3MAP4K1 | |
| SCHEMBL7984131 | 0.76 | MAPK1 (0.53) | MAPK1MAPK3FLT3TTKPDE2A | |
| SCHEMBL5379586 | 0.76 | MAPK1 (0.54) | MAPK1MAPK3FLT3MAPK8 | |
| SCHEMBL13198201 | 0.76 | — | — | |
| SCHEMBL2867158 | 0.76 | — | — | |
| SCHEMBL31172213 | 0.76 | FLT3 (0.64) | MAPK1MAPK3FLT3MAPK8 | |
| SCHEMBL7979377 | 0.75 | MAPK1 (0.50) | MAPK1MAPK3TTK | |
| SCHEMBL8258377 | 0.74 | FLT3 (0.62) | MAPK1MAPK3FLT3MAPK8 | |
| SCHEMBL4923456 | 0.73 | FLT3 (0.63) | FLT3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAPK1 52/4885MAPK3 4/4885FLT3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.